A 12-month post-treatment threshold effectively differentiates early from late progression in CLL, impacting survival outcomes significantly. Early progression within 12 months post-treatment ...

The U.S. Food and Drug Administration (FDA) has expanded the approved indication for pirtobrutinib (Jaypirca) to include the treatment of adult patients with previously untreated ...

The FDA expanded the approval of pirtobrutinib to include initial treatment of adults with chronic lymphocytic leukemia or small lymphocytic leukemia with no known 17p deletion. Pirtobrutinib ...

Discover expert tips to improve sleep for people with chronic lymphocytic leukemia, including routines, environment tweaks, ...

Assess the role of risk stratification, MRD assessment, and resistance mechanisms in treatment selection and personalization for patients with CLL across multiple therapy lines. Analyze trial results ...

Chronic lymphocytic leukemia (CLL), the most common leukemia of adults in Western countries, is standing at a genuine ...

Learn why chronic lymphocytic leukemia (CLL) causes persistent exhaustion, explore common triggers, and discover practical ...

During chronic lymphocytic leukemia (CLL) management, youll need to follow your care teams recommendations and stick to your treatment plan. However, another crucial part of managing CLL involves ...

Not long ago, treatment for chronic lymphocytic leukemia (CLL) often meant needing chemotherapy or a targeted medication for the rest of your life, as long as you tolerated it and your doctor could ...

Joanna Rhodes, MD, MSCE, highlights significant racial and ethnic disparities that persist in access to preferred CLL treatments. What do your findings reveal about the magnitude of racial and ethnic ...

CLL and its treatment can weaken the immune system, increasing the risk of complications such as infections and a second cancer. People can lower the risk of complications with various strategies and ...